262 related articles for article (PubMed ID: 14558081)
1. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
Yazici Y; Erkan D; Paget SA
Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
Genovese MC; Cohen S; Moreland L; Lium D; Robbins S; Newmark R; Bekker P;
Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
[TBL] [Abstract][Full Text] [Related]
3. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
[TBL] [Abstract][Full Text] [Related]
4. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
[TBL] [Abstract][Full Text] [Related]
5. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
7. Infections in patients with rheumatoid arthritis treated with biologic agents.
Listing J; Strangfeld A; Kary S; Rau R; von Hinueber U; Stoyanova-Scholz M; Gromnica-Ihle E; Antoni C; Herzer P; Kekow J; Schneider M; Zink A
Arthritis Rheum; 2005 Nov; 52(11):3403-12. PubMed ID: 16255017
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
9. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
[TBL] [Abstract][Full Text] [Related]
10. Examining the efficacy of biologic therapy: are there real differences?
Fleischmann RM
J Rheumatol Suppl; 2002 Sep; 65():27-32. PubMed ID: 12236619
[TBL] [Abstract][Full Text] [Related]
11. Anakinra: new preparation. Weakly effective in rheumatoid arthritis.
Prescrire Int; 2004 Apr; 13(70):43-5. PubMed ID: 15148945
[TBL] [Abstract][Full Text] [Related]
12. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
13. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
Kristensen LE; Saxne T; Geborek P
Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
15. Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
Zink A; Listing J; Kary S; Ramlau P; Stoyanova-Scholz M; Babinsky K; von Hinueber U; Gromnica-Ihle E; Wassenberg S; Antoni C; Herzer P; Kekow J; Schneider M; Rau R
Ann Rheum Dis; 2005 Sep; 64(9):1274-9. PubMed ID: 15708884
[TBL] [Abstract][Full Text] [Related]
16. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
17. Infliximab therapy in established rheumatoid arthritis: an observational study.
Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
[TBL] [Abstract][Full Text] [Related]
18. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
Maetzel A; Bombardier C; Strand V; Tugwell P; Wells G
J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426
[TBL] [Abstract][Full Text] [Related]
19. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
20. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
Chakravarty EF; Sanchez-Yamamoto D; Bush TM
J Rheumatol; 2003 Feb; 30(2):241-6. PubMed ID: 12563675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]